Bisabolol
Especificaciones
515-69-5Número CAS
246-973-7Número CE
(2R)-6-methyl-2-[(1R)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-olNombre IUPAC
C15H26OFórmula química
222.37 g/molPeso molecular
Bisabolol; 515-69-5; DTXSID5045964; 36HQN158VC; DTXCID3025964; 5-HEPTEN-2-OL, 6-METHYL-2-(4-METHYL-3-CYCLOHEXEN-1-YL)-; 3-Cyclohexene-1-methanol, alpha,4-dimethyl-alpha-(4-methyl-3-pentenyl)-, (alphaR,1R)-rel-; 3-Cyclohexene-1-methanol, alpha,4-dimethyl-alpha-(4-methyl-3-pentenyl)-, (R*,R*)-; 3-Cyclohexene-1-methanol, alpha,4-dimethyl-alpha-(4-methyl-3-penten-1-yl)-, (alphaR,1R)-rel-; GZE Skincare Oil; Bisabolol 0.5%; RefChem:917307; 208-205-9; alpha-Bisabolol; (+)-alpha-Bisabolol; 23178-88-3; (2R)-6-methyl-2-[(1R)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-ol; D-alpha-Bisabolol; (aR,1R)-a-Bisabolol; (R)-6-Methyl-2-((R)-4-methylcyclohex-3-en-1-yl)hept-5-en-2-ol; rel-(R)-6-Methyl-2-((R)-4-methylcyclohex-3-en-1-yl)hept-5-en-2-ol; (+)-(1'R,2R)-alpha-Bisabolol; MFCD03846910; Dragosantol; Camilol; (AlphaR,1R)-Alpha-Bisabolol; CHEMBL1171719; Hydagen B; 105S6I733Z; (2R)-6-Methyl-2-(4-methyl-3-cyclohexenyl)-5-heptene-2-ol; (+/-)-alpha-Bisabolol; 3-Cyclohexene-1-methanol, .alpha.,4-dimethyl-.alpha.-(4-methyl-3-pentenyl)-, (R*,R*)-; alpha,4-Dimethyl-alpha-(4-methyl-3-pentenyl)-3-cyclohexene-1-methanol; dl-.alpha.-Bisabolol; BISABOLOL, ALPHA; CAS-515-69-5; BISABOLOL, .ALPHA.; RACEMIC ALFA-BISABOLOL; alpha-Bisabolol, (+)-; 2,10-Bisaboladien-7-ol; UNII-36HQN158VC; BISABOLA-1,12-DIEN-8-OL; alpha,4-dimethyl-alpha-[4-methyl-3-pentenyl]-3-cyclohexene-1-methanol; UNII-105S6I733Z; alpha-Bisabolol (+)-form [MI]; NCGC00095252-01; (+)-a-Bisabolol; EINECS 208-205-9; EINECS 246-973-7; (+)-alpha Bisabolol; (+/-)alpha-Bisabolol; (+)-.alpha.-Bisabolol; BISABOLOL [WHO-DD]; 3-Cyclohexene-1-methanol, alpha,4-dimethyl-alpha-(4-methyl-3-penten-1-yl)-, (alphaR,1R)-; D-.ALPHA.-BISABOLOL; SCHEMBL24988; (+)-6R,7R-alpha-Bisabolol; .alpha.,4-Dimethyl-.alpha.-(4-methyl-3-pentenyl)-3-cyclohexene-1-methanol; .ALPHA.-BISABOLOL [MI]; BISABOLOL, (+/-)-; SCHEMBL31157846; (R*,R*)-.alpha.,4-Dimethyl-.alpha.-(4-methyl-3-pentenyl)-3-cyclohexene-1-methanol; (R*,R*)-.alpha.,4-Dimethyl-.alpha.-(4-methyl-3-pentenyl)cyclohex-3-ene-1-methanol; CHEBI:192031; ALPHA-BISABOLOL, (+-)-; DTXSID001370999; 3-Cyclohexene-1-methanol, .alpha.,4-dimethyl-.alpha.-(4-methyl-3-penten-1-yl)-, (.alpha.R,1R)-rel-; (+/-)-.ALPHA.-BISABOLOL; .ALPHA.-BISABOLOL, (+)-; Tox21_111490; BDBM50284328; MSK158680; AKOS015969722; Tox21_111490_1; .ALPHA.-BISABOLOL, (+/-)-; EBC-618365; (R*,R*)-alpha,4-Dimethyl-alpha-(4-methyl-3-pentenyl)cyclohex-3-ene-1-methanol; NCGC00095252-05; 25428-43-7; .ALPHA.-BISABOLOL (+)-FORM [MI]; HY-121222; (+)-(1'R,2R)-.ALPHA.-BISABOLOL; CS-0081254; 3-Cyclohexene-1-methanol, alpha,4-dimethyl-alpha-(4-methyl-3-pentenyl)-; (R*,R*)-(1)-alpha,4-Dimethyl-alpha-(4-methyl-3-pentenyl)cyclohex-3-ene-1-methanol; |A-bisabolol,6-methyl-2-(4-methyl-3-cyclohexen-1-yl)-5-hepten-2-ol,dragosantol; alpha,4-Dimethyl-alpha-(4-methyl-3-penten-1-yl)-(alphaR,1R)-3-Cyclohexene-1-methanol; 3-CYCLOHEXENE-1-METHANOL, .ALPHA.,4-DIMETHYL-.ALPHA.-(4-METHYL- 3-PENTEN-1-YL)-, (.ALPHA.R,1R)-REL-; 3-CYCLOHEXENE-1-METHANOL, .ALPHA.,4-DIMETHYL-.ALPHA.-(4-METHYL- 3-PENTENYL)-, (.THETA.,.THETA.)-(+/-)-; 3-CYCLOHEXENE-1-METHANOL, .ALPHA.,4-DIMETHYL-.ALPHA.-(4-METHYL- 3-PENTENYL)-, (R*,R*)-; 3-CYCLOHEXENE-1-METHANOL, .ALPHA.,4-DIMETHYL-.ALPHA.-(4-METHYL-3-PENTEN-1-YL)-, (.ALPHA.R,1R)-; 3-Cyclohexene-1-methanol, alpha,4-dimethyl-alpha-(4-methyl-3-pentenyl)-, (theta,theta)-(+/-)-Sinónimos
